Clinical Observation Of Jiawei Chaishao Liujunzi Decoction And Ganxi Tablets Combined With TACE In The Treatment Of Primary Liver Cancer (liver Stasis And Spleen Deficiency, Internal Damp-heat Type)

Objective:To explore the clinical efficacy and safety of Jiawei Chai Shao Liu Junzi Decoction and Ganxi Tablets combined with TACE in the treatment of primary liver cancer,and to provide safe and effective comprehensive treatment schemes for integrated liver and Chinese medicine for patients with primary liver cancer.Methods:Using a prospective cohort study method with non-randomized,concurrent control,60 patients who met the inclusion criteria were divided into a test group and a control group according to the recommendations of patients,30 cases in each group.In the control group,a single TACE(oxaliplatin 60-100mg/m2+pirarubicin 20mg/m2,and 15-20m L of super liquified iodized oil suspension)was used to embolize tumor blood vessels(every 4 weeks)1 course of treatment,a total of3 courses of observation);the treatment group plan adopts TACE(same as the control group)combined with modified Chai Shao Liu Junzi Decoction and Gan Xi tablets(1dose of Chinese medicine daily,decoction once,take 400ml of juice,divide 2.Warm taking twice in the afternoon,200ml each time;Chinese patent medicine:Ganxi tablets,6 tablets each time,3 times a day.Take it from the day after the completion of TACE),every 4 weeks 1 course,a total of 3 observations Course of treatment:Assess the patient's liver function,immune function,quality of life,the occurrence of postoperative embolism syndrome,TCM symptom score,tumor changes,physical status,and progression-free survival.Results:(1)the liver function:ALT,AST,TBIL in treatment group after treatment than before treatment,control group ALT,AST,TBIL was rising,the two groups have significant difference each index statistical significance(P<0.01)and(2)the immune function:the treatment group and control group after treatment of CD3~+,CD4~+,CD4~+/CD8~+values are rising,the difference between the two groups have statistically significant difference(P<0.01),the two groups after treatment CD8~+were decreased,and the treatment group decreased more significantly,the difference was statistically significant(P<0.05);(3)QOL score of liver cancer quality of life:after treatment,QOL score of liver cancer in the treatment group increased more significantly than that in the control group in terms of physical,psychological,symptom and total score of life quality,and the difference between the two groups was statistically significant(P<0.01).After treatment,the scores of social dimension of the two groups decreased,but there was no statistical difference between the two groups(P>0.05).(4)postoperative embolization syndrome:the incidence of fever,nausea,vomiting and abdominal distension after each cycle of treatment in the treatment group was lower than that in the control group,and there were statistically significant differences between the two groups(P<0.05).In terms of improving symptoms of constipation,there were no statistically significant differences between the two groups(P>0.05).(5)TCM syndrome score:the total effective rate was 80%in the treatment group and 53.3%in the control group;The comparison between the two groups was statistically significant(P<0.05).(6)Physical strength score:after treatment,the effective rate of the treatment group was 93.3%,and the effective rate of the control group was 86.7%.The difference between the two groups was statistically significant(P<0.05).(7)Alpha-fetoprotein:AFP decreased in both groups after treatment compared with that before treatment(P<0.05),and the improvement degree of the treatment group was better than that of the control group after treatment(P<0.05);(8)Evaluation of tumor changes:after treatment,ORR(CR+PR)and disease control rate(CR+PR+SD)were 20%and 83.3%respectively.RR was 13%in the control group,and the disease control rate was 80%.There was no statistical significance between the two groups(P>0.05).(9)progression-free survival:the median PFS was 6.2 months in the treatment group and 5.9 months in the control group,with no statistical difference(P>0.05).Conclusion:Jiawei Chai Shao Liujunzi Decoction and Ganxi Tablets combined with TACE in the treatment of primary liver cancer with liver depression and spleen deficiency and damp heat content can better reduce liver function damage,improve patient immunity,improve patient quality of life,and reduce postoperative embolism.The occurrence of symptoms and the reduction of serum AFP levels indicate that the combined traditional Chinese medicine treatment method of Jiawei Chai Shao Liu Junzi Decoction and Gan Xi Tablets combined with TACE is an effective way to treat primary liver cancer with integrated Chinese and Western medicine.